BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36917758)

  • 1. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
    Lazzeroni M; Puntoni M; Guerrieri-Gonzaga A; Serrano D; Boni L; Buttiron Webber T; Fava M; Briata IM; Giordano L; Digennaro M; Cortesi L; Falcini F; Serra P; Avino F; Millo F; Cagossi K; Gallerani E; De Simone A; Cariello A; Aprile G; Renne M; Bonanni B; DeCensi A
    J Clin Oncol; 2023 Jun; 41(17):3116-3121. PubMed ID: 36917758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
    DeCensi A; Puntoni M; Guerrieri-Gonzaga A; Caviglia S; Avino F; Cortesi L; Taverniti C; Pacquola MG; Falcini F; Gulisano M; Digennaro M; Cariello A; Cagossi K; Pinotti G; Lazzeroni M; Serrano D; Branchi D; Campora S; Petrera M; Buttiron Webber T; Boni L; Bonanni B
    J Clin Oncol; 2019 Jul; 37(19):1629-1637. PubMed ID: 30973790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Land S; Mamounas E; Dignam J; Fisher ER; Wolmark N
    Semin Oncol; 2001 Aug; 28(4):400-18. PubMed ID: 11498833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
    Cuzick J; Sestak I; Pinder SE; Ellis IO; Forsyth S; Bundred NJ; Forbes JF; Bishop H; Fentiman IS; George WD
    Lancet Oncol; 2011 Jan; 12(1):21-9. PubMed ID: 21145284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative tamoxifen for ductal carcinoma in situ.
    Staley H; McCallum I; Bruce J
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
    Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
    Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast.
    Lazzeroni M; Puntoni M; Provinciali N; Webber TB; Briata IM; D'Amico M; Giuliano S; Siri G; Cagnacci S; DeCensi A
    Breast; 2019 Nov; 48 Suppl 1():S39-S43. PubMed ID: 31839158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
    Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
    J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
    Renshaw AA; Gould EW
    Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.
    Ottesen GL; Graversen HP; Blichert-Toft M; Christensen IJ; Andersen JA
    Breast Cancer Res Treat; 2000 Aug; 62(3):197-210. PubMed ID: 11072784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences.
    Cutuli B; Wiezzane N; Palumbo I; Barbieri P; Guenzi M; Huscher A; Borghesi S; Delva C; Iannone T; Vianello E; Rosetto ME; Aristei C
    Cancer Radiother; 2016 Jun; 20(4):292-8. PubMed ID: 27344537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
    Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
    Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
    Staley H; McCallum I; Bruce J
    Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
    Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
    Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ.
    Miller ME; Muhsen S; Zabor EC; Flynn J; Olcese C; Giri D; Van Zee KJ; Pilewskie M
    Ann Surg Oncol; 2019 Dec; 26(13):4317-4325. PubMed ID: 31552614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
    Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
    Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis.
    Stuart KE; Houssami N; Taylor R; Hayen A; Boyages J
    BMC Cancer; 2015 Nov; 15():890. PubMed ID: 26555555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
    Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
    Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.